Literature DB >> 15370364

Involvement of cyclooxygenase-2 in rat models of conjunctivitis.

Takayuki Oka1, Thomas Shearer, Mitsuyoshi Azuma.   

Abstract

PURPOSE: Using two animal models to determine which isoform of cyclooxygenase (COX), constitutive COX-1 or inducible COX-2, is involved in the progression of anterior ocular inflammation.
METHODS: Lambda-carrageenan (500 mg/eye) or bacterial lipopolysaccharide (LPS; 3 mg/eye) was injected into rat conjunctiva to induce conjunctivitis. Vascular permeability in inflamed conjunctiva was measured by uptake of systemic Evans blue. Changes in mRNA for COX-1 and COX-2 in conjunctiva were detected by RT-PCR. Changes in COX-2 protein were detected by immunoblotting after immunoprecipitation. To assess involvement of COX-2 in carrageenan and LPS-induced conjunctivitis, NS-398 (a selective COX-2 inhibitor) or indomethacin (non-selective COX inhibitor) was topically administrated at 15 and 30 minutes before inflammatory stimulator-injection.
RESULTS: In the carrageenan-injected model, the dye content of conjunctiva (12.4 +/- 2.8 mg/eye) was significantly increased 4 hours after injection compared to saline-injected control rats (3.7 +/-1.1 mg/eye). mRNA for COX-2 was significantly increased by 2 hours and gradually increased until 24 hours; COX-1 mRNA did not show major changes until 24 hours after injection. COX-2 protein was markedly elevated 4 hours after injection of carrageenan. COX-2 protein levels were well correlated with increased mRNA levels. In the LPS-injected model, the dye content of conjunctiva (5.8 +/- 1.2 mg/eye) was significantly increased 4 hours after injection compared to saline-injected control rats (3.1 +/- 0.6 mg/eye). Expression of COX-2 mRNA was increased 1 hour after injection, peaked at 2 hours, and decreased at 4 hours. mRNA for COX-1 did not change by 24 hours. COX- 2 protein increased 2 hours after injection of LPS. COX-2 protein levels were well correlated with increased mRNA. Topical administration of 1% NS-398 exhibited strong inhibition of dye-leakage into conjunctiva 4 hours after injection of carrageenan or LPS, since 59% or 83% of dye-uptake were inhibited, respectively. 1% of indomethacin eye drops showed only a minimal effect.
CONCLUSIONS: These results suggest that the mechanism for anterior ocular inflammation may be due to up-regulation of COX-2.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15370364     DOI: 10.1080/02713680490513164

Source DB:  PubMed          Journal:  Curr Eye Res        ISSN: 0271-3683            Impact factor:   2.424


  9 in total

1.  Bromfenac ophthalmic solution 0.09 %: human aqueous humor concentration detected by high-performance liquid chromatography.

Authors:  Angelo Macrì; Aldo Vagge; Annalisa Salis; Carmen Fucile; Valeria Marini; Antonietta Martelli; Sebastiano Giuffrida; Michele Iester; Gianluca Damonte; Francesca Mattioli
Journal:  Int Ophthalmol       Date:  2016-06-20       Impact factor: 2.031

2.  Topical nonsteroidal anti-inflammatory drugs as adjuvant therapy in the prevention of macular edema after cataract surgery.

Authors:  Nicola Cardascia; Carmela Palmisano; Tersa Centoducati; Giovanni Alessio
Journal:  Int Ophthalmol       Date:  2016-10-20       Impact factor: 2.031

3.  Management of ocular inflammation and pain following cataract surgery: focus on bromfenac ophthalmic solution.

Authors:  Hyung Cho; Kenneth J Wolf; Eric J Wolf
Journal:  Clin Ophthalmol       Date:  2009-06-02

Review 4.  Topical bromfenac for prevention and treatment of cystoid macular edema following cataract surgery: a review.

Authors:  John D Sheppard
Journal:  Clin Ophthalmol       Date:  2016-10-25

5.  An ex vivo human aqueous humor-concentration comparison of two commercial bromfenac formulations.

Authors:  Thomas R Walters; Robert J Smyth-Medina; Paul C Cockrum
Journal:  Clin Ophthalmol       Date:  2018-05-21

6.  Effect of 0.1% Bromfenac for Preventing Macular Edema after Cataract Surgery in Patients with Diabetes.

Authors:  Seok Hyeon Song; Seung Kook Baek; Min Woo Lee; Young Hoon Lee
Journal:  Korean J Ophthalmol       Date:  2020-02

7.  Update on twice-daily bromfenac sodium sesquihydrate to treat postoperative ocular inflammation following cataract extraction.

Authors:  Ester Carreño; Alejandro Portero; David J Galarreta; José M Herreras
Journal:  Clin Ophthalmol       Date:  2012-04-27

8.  The ocular distribution of (14)C-labeled bromfenac ophthalmic solution 0.07% in a rabbit model.

Authors:  George A Baklayan; Mauricio Muñoz
Journal:  Clin Ophthalmol       Date:  2014-09-04

9.  In Vivo Pharmacokinetics of Bromfenac Ophthalmic Solution 0.075%, Bromfenac Ophthalmic Solution 0.07%, and Nepafenac/Amfenac Ophthalmic Suspension 0.3% in Rabbits.

Authors:  John D Sheppard; Paul C Cockrum; Angela Justice; Mark C Jasek
Journal:  Ophthalmol Ther       Date:  2018-05-14
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.